Maurie Markman, MD, president of medicine and science, Cancer Treatment Centers of America, discusses valuable endpoints beyond overall survival (OS) that can be used in ovarian cancer clinical trials.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More